CCDC50
Coiled-coil domain-containing protein 50
Protein Summary
Involved in EGFR signaling. This gene encodes a soluble, cytoplasmic, tyrosine-phosphorylated protein with multiple ubiquitin-interacting domains. Mutations in this gene cause nonsyndromic, postlingual, progressive sensorineural DFNA44 hearing loss. In mouse, the protein is expressed in the inner ear during development and postnatal maturation and associates with microtubule-based structures. This protein may also function as a negative regulator of NF-kB signaling and as an effector of epidermal growth factor (EGF)-mediated cell signaling. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Oct 2008]
- ENST00000392455
- ENSP00000376249
- ENSG00000152492
- ENST00000392456
- ENSP00000376250
- C3orf6
- YMER
- C3orf6
- DFNA44
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
transcription factor perturbation | 0.97 | ||
cell type or tissue | 0.87 | ||
ligand (protein) perturbation | 0.83 | ||
microRNA | 0.8 | ||
interacting protein | 0.71 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 31.79 (req: < 5)
Gene RIFs: 10 (req: <= 3)
Antibodies: 219 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 31.79 (req: >= 5)
Gene RIFs: 10 (req: > 3)
Antibodies: 219 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 2
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0